|
1
|
Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MB, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NW, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S. Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. Hemasphere 2023; 7:e940. [PMID: 37663673 PMCID: PMC10470677 DOI: 10.1097/hs9.0000000000000940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 07/07/2023] [Indexed: 09/05/2023] Open
Affiliation(s)
- Kazimierz Groen
- Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
- Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands
| | - Fredrik H. Schjesvold
- Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, Norway
- KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway
| | - Bronno van der Holt
- Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Mark-David Levin
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands
| | - Maarten R. Seefat
- Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
- Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands
| | - Markus Hansson
- Department of Hematology, Skåne University Hospital Lund, Sweden
| | - Maria B.L. Leys
- Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands
| | - Josien C. Regelink
- Department of Internal Medicine, Meander Medical Centre, Amersfoort, the Netherlands
| | - Anders Waage
- Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
| | - Damian Szatkowski
- Department of Oncology and Hematology, Førde Central Hospital, Norway
| | - Per Axelsson
- Department of Internal Medicine, Helsingborg Hospital, Sweden
| | - Trung Hieu Do
- Haematology Department H 60, Roskilde Sjaelland University, Denmark
| | - Asta Svirskaite
- Department of Hematology, Aalborg University Hospital, Denmark
| | - Ellen van der Spek
- Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands
| | - Einar Haukas
- Department for Blood and Cancer Diseases, Stavanger University Hospital, Norway
| | | | - Paula F. Ypma
- Department of Hematology, Haga Hospital, The Hague, the Netherlands
| | - Cecilie H. Blimark
- Hematology Department, Sahlgrenska University Hospital, Gothenburg, Sweden
| | | | - Niels W.C.J. van de Donk
- Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
- Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands
| | - Pieter Sonneveld
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | | | | | - Niels Abildgaard
- Department of Hematology, Hematology Research Unit and Academy of Geriatric Research, Odense University Hospital and University of Southern Denmark, Denmark
| | - Sonja Zweegman
- Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
- Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands
| |
Collapse
|
|
2
|
Rokx C, Swart RM, van Houten AA, Leys MB, Duvekot JJ, Te Boekhorst PAW. [Thrombocytopenia during pregnancy]. Ned Tijdschr Geneeskd 2013; 157:A6445. [PMID: 23945435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Thrombocytopenia during pregnancy can be caused by a broad variety of disorders. An early diagnosis is essential for timely and adequate therapy. In cases of severe thrombocytopenia, a multidisciplinary approach by a team of obstetricians, haematologists and anaesthesiologists is needed. We describe a 30-year-old patient at a gestational age of 35 weeks who presented with preterm rupture of membranes. Coincidentally, she also had severe thrombocytopenia that proved to be due to immune thrombocytopenia (ITP). The severe thrombocytopenia persisted despite standard first-line treatment with corticosteroids and intravenous immunoglobulins. Based on this case report we discuss the differential diagnosis of thrombocytopenia during pregnancy with a focus on the management of ITP in pregnant women.
Collapse
Affiliation(s)
- C Rokx
- Erasmus Medisch Centrum, Rotterdam
| | | | | | | | | | | |
Collapse
|